1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by ER Targeted Drugs for Breast Cancer Revenue 1.4 Market Analysis by Type 1.4.1 Global ER Targeted Drugs for Breast Cancer Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Tamoxifen 1.4.3 Toremifene 1.4.4 Fulvestrant 1.5 Market by Application 1.5.1 Global ER Targeted Drugs for Breast Cancer Market Share by Application: 2020 VS 2026 1.5.2 Hospital 1.5.3 Clinic 1.5.4 Drug Center 1.5.5 Other 1.6 Coronavirus Disease 2019 (Covid-19): ER Targeted Drugs for Breast Cancer Industry Impact 1.6.1 How the Covid-19 is Affecting the ER Targeted Drugs for Breast Cancer Industry 1.6.1.1 ER Targeted Drugs for Breast Cancer Business Impact Assessment - Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and ER Targeted Drugs for Breast Cancer Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for ER Targeted Drugs for Breast Cancer Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered 2 Global Growth Trends by Regions 2.1 ER Targeted Drugs for Breast Cancer Market Perspective (2015-2026) 2.2 ER Targeted Drugs for Breast Cancer Growth Trends by Regions 2.2.1 ER Targeted Drugs for Breast Cancer Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 ER Targeted Drugs for Breast Cancer Historic Market Share by Regions (2015-2020) 2.2.3 ER Targeted Drugs for Breast Cancer Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 ER Targeted Drugs for Breast Cancer Market Growth Strategy 2.3.6 Primary Interviews with Key ER Targeted Drugs for Breast Cancer Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top ER Targeted Drugs for Breast Cancer Players by Market Size 3.1.1 Global Top ER Targeted Drugs for Breast Cancer Players by Revenue (2015-2020) 3.1.2 Global ER Targeted Drugs for Breast Cancer Revenue Market Share by Players (2015-2020) 3.1.3 Global ER Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global ER Targeted Drugs for Breast Cancer Market Concentration Ratio 3.2.1 Global ER Targeted Drugs for Breast Cancer Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by ER Targeted Drugs for Breast Cancer Revenue in 2019 3.3 ER Targeted Drugs for Breast Cancer Key Players Head office and Area Served 3.4 Key Players ER Targeted Drugs for Breast Cancer Product Solution and Service 3.5 Date of Enter into ER Targeted Drugs for Breast Cancer Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global ER Targeted Drugs for Breast Cancer Historic Market Size by Type (2015-2020) 4.2 Global ER Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2021-2026) 5 ER Targeted Drugs for Breast Cancer Breakdown Data by Application (2015-2026) 5.1 Global ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) 5.2 Global ER Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America ER Targeted Drugs for Breast Cancer Market Size (2015-2020) 6.2 ER Targeted Drugs for Breast Cancer Key Players in North America (2019-2020) 6.3 North America ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) 6.4 North America ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) 7 Europe 7.1 Europe ER Targeted Drugs for Breast Cancer Market Size (2015-2020) 7.2 ER Targeted Drugs for Breast Cancer Key Players in Europe (2019-2020) 7.3 Europe ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) 7.4 Europe ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) 8 China 8.1 China ER Targeted Drugs for Breast Cancer Market Size (2015-2020) 8.2 ER Targeted Drugs for Breast Cancer Key Players in China (2019-2020) 8.3 China ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) 8.4 China ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) 9 Japan 9.1 Japan ER Targeted Drugs for Breast Cancer Market Size (2015-2020) 9.2 ER Targeted Drugs for Breast Cancer Key Players in Japan (2019-2020) 9.3 Japan ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) 9.4 Japan ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia ER Targeted Drugs for Breast Cancer Market Size (2015-2020) 10.2 ER Targeted Drugs for Breast Cancer Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) 10.4 Southeast Asia ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) 11 India 11.1 India ER Targeted Drugs for Breast Cancer Market Size (2015-2020) 11.2 ER Targeted Drugs for Breast Cancer Key Players in India (2019-2020) 11.3 India ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) 11.4 India ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America ER Targeted Drugs for Breast Cancer Market Size (2015-2020) 12.2 ER Targeted Drugs for Breast Cancer Key Players in Central & South America (2019-2020) 12.3 Central & South America ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) 12.4 Central & South America ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) 13 Key Players Profiles 13.1 AstraZeneca 13.1.1 AstraZeneca Company Details 13.1.2 AstraZeneca Business Overview and Its Total Revenue 13.1.3 AstraZeneca ER Targeted Drugs for Breast Cancer Introduction 13.1.4 AstraZeneca Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)) 13.1.5 AstraZeneca Recent Development 13.2 Sanofi 13.2.1 Sanofi Company Details 13.2.2 Sanofi Business Overview and Its Total Revenue 13.2.3 Sanofi ER Targeted Drugs for Breast Cancer Introduction 13.2.4 Sanofi Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 13.2.5 Sanofi Recent Development 13.3 Pfizer 13.3.1 Pfizer Company Details 13.3.2 Pfizer Business Overview and Its Total Revenue 13.3.3 Pfizer ER Targeted Drugs for Breast Cancer Introduction 13.3.4 Pfizer Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 13.3.5 Pfizer Recent Development 13.4 Mylan  13.4.1 Mylan  Company Details 13.4.2 Mylan  Business Overview and Its Total Revenue 13.4.3 Mylan  ER Targeted Drugs for Breast Cancer Introduction 13.4.4 Mylan  Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 13.4.5 Mylan  Recent Development 13.5 Wockhardt 13.5.1 Wockhardt Company Details 13.5.2 Wockhardt Business Overview and Its Total Revenue 13.5.3 Wockhardt ER Targeted Drugs for Breast Cancer Introduction 13.5.4 Wockhardt Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 13.5.5 Wockhardt Recent Development 13.6 Cipla 13.6.1 Cipla Company Details 13.6.2 Cipla Business Overview and Its Total Revenue 13.6.3 Cipla ER Targeted Drugs for Breast Cancer Introduction 13.6.4 Cipla Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 13.6.5 Cipla Recent Development 13.7 Actiza Pharmaceutical 13.7.1 Actiza Pharmaceutical Company Details 13.7.2 Actiza Pharmaceutical Business Overview and Its Total Revenue 13.7.3 Actiza Pharmaceutical ER Targeted Drugs for Breast Cancer Introduction 13.7.4 Actiza Pharmaceutical Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 13.7.5 Actiza Pharmaceutical Recent Development 13.8 Teva 13.8.1 Teva Company Details 13.8.2 Teva Business Overview and Its Total Revenue 13.8.3 Teva ER Targeted Drugs for Breast Cancer Introduction 13.8.4 Teva Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 13.8.5 Teva Recent Development 13.9 Shanghai Forward Technology 13.9.1 Shanghai Forward Technology Company Details 13.9.2 Shanghai Forward Technology Business Overview and Its Total Revenue 13.9.3 Shanghai Forward Technology ER Targeted Drugs for Breast Cancer Introduction 13.9.4 Shanghai Forward Technology Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 13.9.5 Shanghai Forward Technology Recent Development 13.10 Bayer 13.10.1 Bayer Company Details 13.10.2 Bayer Business Overview and Its Total Revenue 13.10.3 Bayer ER Targeted Drugs for Breast Cancer Introduction 13.10.4 Bayer Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 13.10.5 Bayer Recent Development 13.11 Liaoning Kangtai Pharmaceutical 10.11.1 Liaoning Kangtai Pharmaceutical Company Details 10.11.2 Liaoning Kangtai Pharmaceutical Business Overview and Its Total Revenue 10.11.3 Liaoning Kangtai Pharmaceutical ER Targeted Drugs for Breast Cancer Introduction 10.11.4 Liaoning Kangtai Pharmaceutical Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 10.11.5 Liaoning Kangtai Pharmaceutical Recent Development 13.12 Fu 'an Pharmaceutical Group 10.12.1 Fu 'an Pharmaceutical Group Company Details 10.12.2 Fu 'an Pharmaceutical Group Business Overview and Its Total Revenue 10.12.3 Fu 'an Pharmaceutical Group ER Targeted Drugs for Breast Cancer Introduction 10.12.4 Fu 'an Pharmaceutical Group Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 10.12.5 Fu 'an Pharmaceutical Group Recent Development 13.13 Yangtze River Pharmaceutical Group 10.13.1 Yangtze River Pharmaceutical Group Company Details 10.13.2 Yangtze River Pharmaceutical Group Business Overview and Its Total Revenue 10.13.3 Yangtze River Pharmaceutical Group ER Targeted Drugs for Breast Cancer Introduction 10.13.4 Yangtze River Pharmaceutical Group Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 10.13.5 Yangtze River Pharmaceutical Group Recent Development 13.14 Amneal Pharms 10.14.1 Amneal Pharms Company Details 10.14.2 Amneal Pharms Business Overview and Its Total Revenue 10.14.3 Amneal Pharms ER Targeted Drugs for Breast Cancer Introduction 10.14.4 Amneal Pharms Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 10.14.5 Amneal Pharms Recent Development 13.15 Novartis 10.15.1 Novartis Company Details 10.15.2 Novartis Business Overview and Its Total Revenue 10.15.3 Novartis ER Targeted Drugs for Breast Cancer Introduction 10.15.4 Novartis Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 10.15.5 Novartis Recent Development 13.16 Intas Pharmaceuticals 10.16.1 Intas Pharmaceuticals Company Details 10.16.2 Intas Pharmaceuticals Business Overview and Its Total Revenue 10.16.3 Intas Pharmaceuticals ER Targeted Drugs for Breast Cancer Introduction 10.16.4 Intas Pharmaceuticals Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 10.16.5 Intas Pharmaceuticals Recent Development 13.17 Chemo 10.17.1 Chemo Company Details 10.17.2 Chemo Business Overview and Its Total Revenue 10.17.3 Chemo ER Targeted Drugs for Breast Cancer Introduction 10.17.4 Chemo Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 10.17.5 Chemo Recent Development 13.18 Accure Labs 10.18.1 Accure Labs Company Details 10.18.2 Accure Labs Business Overview and Its Total Revenue 10.18.3 Accure Labs ER Targeted Drugs for Breast Cancer Introduction 10.18.4 Accure Labs Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 10.18.5 Accure Labs Recent Development 13.19 Natco 10.19.1 Natco Company Details 10.19.2 Natco Business Overview and Its Total Revenue 10.19.3 Natco ER Targeted Drugs for Breast Cancer Introduction 10.19.4 Natco Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 10.19.5 Natco Recent Development 13.20 Orion Corporation 10.20.1 Orion Corporation Company Details 10.20.2 Orion Corporation Business Overview and Its Total Revenue 10.20.3 Orion Corporation ER Targeted Drugs for Breast Cancer Introduction 10.20.4 Orion Corporation Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 10.20.5 Orion Corporation Recent Development 13.21 Kyowa Hakko Kirin 10.21.1 Kyowa Hakko Kirin Company Details 10.21.2 Kyowa Hakko Kirin Business Overview and Its Total Revenue 10.21.3 Kyowa Hakko Kirin ER Targeted Drugs for Breast Cancer Introduction 10.21.4 Kyowa Hakko Kirin Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) 10.21.5 Kyowa Hakko Kirin Recent Development 14 Analyst's Viewpoints/Conclusions 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. ER Targeted Drugs for Breast Cancer Key Market Segments Table 2. Key Players Covered: Ranking by ER Targeted Drugs for Breast Cancer Revenue Table 3. Ranking of Global Top ER Targeted Drugs for Breast Cancer Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global ER Targeted Drugs for Breast Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Tamoxifen Table 6. Key Players of Toremifene Table 7. Key Players of Fulvestrant Table 8. COVID-19 Impact Global Market: (Four ER Targeted Drugs for Breast Cancer Market Size Forecast Scenarios) Table 9. Opportunities and Trends for ER Targeted Drugs for Breast Cancer Players in the COVID-19 Landscape Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis Table 11. Key Regions/Countries Measures against Covid-19 Impact Table 12. Proposal for ER Targeted Drugs for Breast Cancer Players to Combat Covid-19 Impact Table 13. Global ER Targeted Drugs for Breast Cancer Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 14. Global ER Targeted Drugs for Breast Cancer Market Size by Regions (US$ Million): 2020 VS 2026 Table 15. Global ER Targeted Drugs for Breast Cancer Market Size by Regions (2015-2020) (US$ Million) Table 16. Global ER Targeted Drugs for Breast Cancer Market Share by Regions (2015-2020) Table 17. Global ER Targeted Drugs for Breast Cancer Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 18. Global ER Targeted Drugs for Breast Cancer Market Share by Regions (2021-2026) Table 19. Market Top Trends Table 20. Key Drivers: Impact Analysis Table 21. Key Challenges Table 22. ER Targeted Drugs for Breast Cancer Market Growth Strategy Table 23. Main Points Interviewed from Key ER Targeted Drugs for Breast Cancer Players Table 24. Global ER Targeted Drugs for Breast Cancer Revenue by Players (2015-2020) (Million US$) Table 25. Global ER Targeted Drugs for Breast Cancer Market Share by Players (2015-2020) Table 26. Global Top ER Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in ER Targeted Drugs for Breast Cancer as of 2019) Table 27. Global ER Targeted Drugs for Breast Cancer by Players Market Concentration Ratio (CR5 and HHI) Table 28. Key Players Headquarters and Area Served Table 29. Key Players ER Targeted Drugs for Breast Cancer Product Solution and Service Table 30. Date of Enter into ER Targeted Drugs for Breast Cancer Market Table 31. Mergers & Acquisitions, Expansion Plans Table 32. Global ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 33. Global ER Targeted Drugs for Breast Cancer Market Size Share by Type (2015-2020) Table 34. Global ER Targeted Drugs for Breast Cancer Revenue Market Share by Type (2021-2026) Table 35. Global ER Targeted Drugs for Breast Cancer Market Size Share by Application (2015-2020) Table 36. Global ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 37. Global ER Targeted Drugs for Breast Cancer Market Size Share by Application (2021-2026) Table 38. North America Key Players ER Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$) Table 39. North America Key Players ER Targeted Drugs for Breast Cancer Market Share (2019-2020) Table 40. North America ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 41. North America ER Targeted Drugs for Breast Cancer Market Share by Type (2015-2020) Table 42. North America ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 43. North America ER Targeted Drugs for Breast Cancer Market Share by Application (2015-2020) Table 44. Europe Key Players ER Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$) Table 45. Europe Key Players ER Targeted Drugs for Breast Cancer Market Share (2019-2020) Table 46. Europe ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 47. Europe ER Targeted Drugs for Breast Cancer Market Share by Type (2015-2020) Table 48. Europe ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 49. Europe ER Targeted Drugs for Breast Cancer Market Share by Application (2015-2020) Table 50. China Key Players ER Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$) Table 51. China Key Players ER Targeted Drugs for Breast Cancer Market Share (2019-2020) Table 52. China ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 53. China ER Targeted Drugs for Breast Cancer Market Share by Type (2015-2020) Table 54. China ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 55. China ER Targeted Drugs for Breast Cancer Market Share by Application (2015-2020) Table 56. Japan Key Players ER Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$) Table 57. Japan Key Players ER Targeted Drugs for Breast Cancer Market Share (2019-2020) Table 58. Japan ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 59. Japan ER Targeted Drugs for Breast Cancer Market Share by Type (2015-2020) Table 60. Japan ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 61. Japan ER Targeted Drugs for Breast Cancer Market Share by Application (2015-2020) Table 62. Southeast Asia Key Players ER Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$) Table 63. Southeast Asia Key Players ER Targeted Drugs for Breast Cancer Market Share (2019-2020) Table 64. Southeast Asia ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 65. Southeast Asia ER Targeted Drugs for Breast Cancer Market Share by Type (2015-2020) Table 66. Southeast Asia ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 67. Southeast Asia ER Targeted Drugs for Breast Cancer Market Share by Application (2015-2020) Table 68. India Key Players ER Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$) Table 69. India Key Players ER Targeted Drugs for Breast Cancer Market Share (2019-2020) Table 70. India ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 71. India ER Targeted Drugs for Breast Cancer Market Share by Type (2015-2020) Table 72. India ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 73. India ER Targeted Drugs for Breast Cancer Market Share by Application (2015-2020) Table 74. Central & South America Key Players ER Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US$) Table 75. Central & South America Key Players ER Targeted Drugs for Breast Cancer Market Share (2019-2020) Table 76. Central & South America ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US$) Table 77. Central & South America ER Targeted Drugs for Breast Cancer Market Share by Type (2015-2020) Table 78. Central & South America ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US$) Table 79. Central & South America ER Targeted Drugs for Breast Cancer Market Share by Application (2015-2020) Table 80. AstraZeneca Company Details Table 81. AstraZeneca Business Overview Table 82. AstraZeneca Product Table 83. AstraZeneca Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 84. AstraZeneca Recent Development Table 85. Sanofi Company Details Table 86. Sanofi Business Overview Table 87. Sanofi Product Table 88. Sanofi Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 89. Sanofi Recent Development Table 90. Pfizer Company Details Table 91. Pfizer Business Overview Table 92. Pfizer Product Table 93. Pfizer Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 94. Pfizer Recent Development Table 95. Mylan  Company Details Table 96. Mylan  Business Overview Table 97. Mylan  Product Table 98. Mylan  Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 99. Mylan  Recent Development Table 100. Wockhardt Company Details Table 101. Wockhardt Business Overview Table 102. Wockhardt Product Table 103. Wockhardt Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 104. Wockhardt Recent Development Table 105. Cipla Company Details Table 106. Cipla Business Overview Table 107. Cipla Product Table 108. Cipla Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 109. Cipla Recent Development Table 110. Actiza Pharmaceutical Company Details Table 111. Actiza Pharmaceutical Business Overview Table 112. Actiza Pharmaceutical Product Table 113. Actiza Pharmaceutical Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 114. Actiza Pharmaceutical Recent Development Table 115. Teva Business Overview Table 116. Teva Product Table 117. Teva Company Details Table 118. Teva Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 119. Teva Recent Development Table 120. Shanghai Forward Technology Company Details Table 121. Shanghai Forward Technology Business Overview Table 122. Shanghai Forward Technology Product Table 123. Shanghai Forward Technology Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 124. Shanghai Forward Technology Recent Development Table 125. Bayer Company Details Table 126. Bayer Business Overview Table 127. Bayer Product Table 128. Bayer Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 129. Bayer Recent Development Table 130. Liaoning Kangtai Pharmaceutical Company Details Table 131. Liaoning Kangtai Pharmaceutical Business Overview Table 132. Liaoning Kangtai Pharmaceutical Product Table 133. Liaoning Kangtai Pharmaceutical Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 134. Liaoning Kangtai Pharmaceutical Recent Development Table 135. Fu 'an Pharmaceutical Group Company Details Table 136. Fu 'an Pharmaceutical Group Business Overview Table 137. Fu 'an Pharmaceutical Group Product Table 138. Fu 'an Pharmaceutical Group Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 139. Fu 'an Pharmaceutical Group Recent Development Table 140. Yangtze River Pharmaceutical Group Company Details Table 141. Yangtze River Pharmaceutical Group Business Overview Table 142. Yangtze River Pharmaceutical Group Product Table 143. Yangtze River Pharmaceutical Group Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 144. Yangtze River Pharmaceutical Group Recent Development Table 145. Amneal Pharms Company Details Table 146. Amneal Pharms Business Overview Table 147. Amneal Pharms Product Table 148. Amneal Pharms Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 149. Amneal Pharms Recent Development Table 150. Novartis Company Details Table 151. Novartis Business Overview Table 152. Novartis Product Table 153. Novartis Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 154. Novartis Recent Development Table 155. Intas Pharmaceuticals Company Details Table 156. Intas Pharmaceuticals Business Overview Table 157. Intas Pharmaceuticals Product Table 158. Intas Pharmaceuticals Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 159. Intas Pharmaceuticals Recent Development Table 160. Chemo Company Details Table 161. Chemo Business Overview Table 162. Chemo Product Table 163. Chemo Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 164. Chemo Recent Development Table 165. Accure Labs Company Details Table 166. Accure Labs Business Overview Table 167. Accure Labs Product Table 168. Accure Labs Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 169. Accure Labs Recent Development Table 170. Natco Company Details Table 171. Natco Business Overview Table 172. Natco Product Table 173. Natco Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 174. Natco Recent Development Table 175. Orion Corporation Company Details Table 176. Orion Corporation Business Overview Table 177. Orion Corporation Product Table 178. Orion Corporation Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 179. Orion Corporation Recent Development Table 180. Kyowa Hakko Kirin Company Details Table 181. Kyowa Hakko Kirin Business Overview Table 182. Kyowa Hakko Kirin Product Table 183. Kyowa Hakko Kirin Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US$) Table 184. Kyowa Hakko Kirin Recent Development Table 185. Research Programs/Design for This Report Table 186. Key Data Information from Secondary Sources Table 187. Key Data Information from Primary Sources List of Figures Figure 1. Global ER Targeted Drugs for Breast Cancer Market Share by Type: 2020 VS 2026 Figure 2. Tamoxifen Features Figure 3. Toremifene Features Figure 4. Fulvestrant Features Figure 5. Global ER Targeted Drugs for Breast Cancer Market Share by Application: 2020 VS 2026 Figure 6. Hospital Case Studies Figure 7. Clinic Case Studies Figure 8. Drug Center Case Studies Figure 9. Other Case Studies Figure 10. ER Targeted Drugs for Breast Cancer Report Years Considered Figure 11. Global ER Targeted Drugs for Breast Cancer Market Size YoY Growth 2015-2026 (US$ Million) Figure 12. Global ER Targeted Drugs for Breast Cancer Market Share by Regions: 2020 VS 2026 Figure 13. Global ER Targeted Drugs for Breast Cancer Market Share by Regions (2021-2026) Figure 14. Porter's Five Forces Analysis Figure 15. Global ER Targeted Drugs for Breast Cancer Market Share by Players in 2019 Figure 16. Global Top ER Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in ER Targeted Drugs for Breast Cancer as of 2019 Figure 17. The Top 10 and 5 Players Market Share by ER Targeted Drugs for Breast Cancer Revenue in 2019 Figure 18. North America ER Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$) Figure 19. Europe ER Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$) Figure 20. China ER Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$) Figure 21. Japan ER Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$) Figure 22. Southeast Asia ER Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$) Figure 23. India ER Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$) Figure 24. Central & South America ER Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$) Figure 25. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018 Figure 26. AstraZeneca Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 27. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018 Figure 28. Sanofi Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 29. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 30. Pfizer Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 31. Mylan  Total Revenue (US$ Million): 2019 Compared with 2018 Figure 32. Mylan  Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 33. Wockhardt Total Revenue (US$ Million): 2019 Compared with 2018 Figure 34. Wockhardt Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 35. Cipla Total Revenue (US$ Million): 2019 Compared with 2018 Figure 36. Cipla Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 37. Actiza Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018 Figure 38. Actiza Pharmaceutical Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 39. Teva Total Revenue (US$ Million): 2019 Compared with 2018 Figure 40. Teva Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 41. Shanghai Forward Technology Total Revenue (US$ Million): 2019 Compared with 2018 Figure 42. Shanghai Forward Technology Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 43. Bayer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 44. Bayer Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 45. Liaoning Kangtai Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018 Figure 46. Liaoning Kangtai Pharmaceutical Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 47. Fu 'an Pharmaceutical Group Total Revenue (US$ Million): 2019 Compared with 2018 Figure 48. Fu 'an Pharmaceutical Group Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 49. Yangtze River Pharmaceutical Group Total Revenue (US$ Million): 2019 Compared with 2018 Figure 50. Yangtze River Pharmaceutical Group Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 51. Amneal Pharms Total Revenue (US$ Million): 2019 Compared with 2018 Figure 52. Amneal Pharms Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 53. Novartis Total Revenue (US$ Million): 2019 Compared with 2018 Figure 54. Novartis Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 55. Intas Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 56. Intas Pharmaceuticals Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 57. Chemo Total Revenue (US$ Million): 2019 Compared with 2018 Figure 58. Chemo Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 59. Accure Labs Total Revenue (US$ Million): 2019 Compared with 2018 Figure 60. Accure Labs Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 61. Natco Total Revenue (US$ Million): 2019 Compared with 2018 Figure 62. Natco Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 63. Orion Corporation Total Revenue (US$ Million): 2019 Compared with 2018 Figure 64. Orion Corporation Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020) Figure 65. Bottom-up and Top-down Approaches for This Report Figure 66. Data Triangulation Figure 67. Key Executives Interviewed

AstraZeneca Sanofi Pfizer Mylan  Wockhardt Cipla Actiza Pharmaceutical Teva Shanghai Forward Technology Bayer Liaoning Kangtai Pharmaceutical Fu 'an Pharmaceutical Group Yangtze River Pharmaceutical Group Amneal Pharms Novartis Intas Pharmaceuticals Chemo Accure Labs Natco Orion Corporation Kyowa Hakko Kirin